

19 Apr 2021 |

Quick Listen: Scrip's Five Must-Know Things

by **Ian Haydock**

In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly's new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi's bullishness on IL-2.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 April 2021, including: adenovirus vaccines and blood clots; Lilly's new moves in genetic diseases; efficacy debate over Chinese COVID vaccines; putting a price tag on innovation; and Sanofi's bullishness on IL-2.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino](#)" - Scrip, 15 Apr, 2021.)

(Also see "[Lilly Takes Another Leap Into Gene Therapy With Jaguar](#)" - Scrip, 13 Apr, 2021.)

(Also see "[Sinovac Real World Data Shed Fresh Light On China COVID Vaccine Efficacy Debate](#)" - Scrip, 14 Apr, 2021.)

(Also see "[Do R&D Spending And Approvals Really Measure Innovation?](#)" - Scrip, 13 Apr, 2021.)

(Also see "[Sanofi Stays Bullish On Synthorx IL-2 Drug, But It's Early Days](#)" - Scrip, 12 Apr, 2021.)

[Click here to explore this interactive content online](#) 